bridgebio attruby news

FDA, Bridgebio

Bridgebio’s Attruby, to Treat Heart Condition ATTR-CM, Receives FDA Approval

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and hospitalization in ATTR-CM patients.

biopharma-reporter · 1h

BridgeBio wins FDA approval for inherited cardiomyopathy treatment

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), an inherited heart condition.

Investor's Business Daily on MSN · 18h

BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug

BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.

BridgeBio price target raised to $45 from $42 at BofA

BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the FDA approved its stabilizer acoramidis as Attruby for ...

BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday

On Friday, the FDA approved BridgeBio Pharma's Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

FDA, Bridgebio

Trending now